Abstract: This invention relates to processes for the preparation of sodium 5,14-dihydrotetraazapentacene polysulfonate (1), and intermediates thereof.

Abstract: The present invention relates to compounds of the formula (1) and to the use thereof in organic electronic devices, and to organic electronic devices which comprise compounds of the formula (1), preferably as hole-transport materials and/or as emitting materials.

Abstract: LED compounds of the general structure: (B-S-)n-A-(-S-B)m (Structure 1); wherein the rod-like molecular nucleus A having the structure: -Ar(-T-Ar)p- (Structure 2); wherein T includes a diradical.

Abstract: Disclosed embodiments concern polycyclic alkaloid compounds and methods for their use and synthesis. Particular embodiments concern polycyclic alkaloids having a fused, six-membered ring, while other embodiments concern polycyclic alkaloids having a fused, five-membered ring. Methods for making the polycyclic alkaloids are disclosed, as well as methods for their use as prophylactics or treatments for certain diseases. Also disclosed are pharmaceutical compositions comprising the polycyclic alkaloids and their use.

Abstract: The invention relates to bimetallic complexes in which the ligand contains a salophen unit which complexes copper, manganese or cobalt and a phenanthroline unit which complexes palladium and the two systems are linked by a continuous conjugated system. The invention further relates to the use of these bimetallic complexes as catalysts for the oxidative carbonylation of aromatic hydroxy compounds to form diaryl carbonates, a process for preparing diaryl carbonates using the bimetallic complex as catalyst and also diaryl carbonates prepared by oxidative carbonylation of aromatic hydroxy compounds using the bimetallic complexes of the invention as catalysts.

Abstract: The present invention provides a novel category of naphthalene-based two-photon fluorescent probes having a general formula I, wherein: X is selected from the X1, X2, X3 and X4; The mentioned two-photon fluorescent probes have a low fluorescence background in the non-tumor cells and tissues, and have a strong and specific fluorescent signal in the tumor cells and tissues. These probes have a certain level of water-solubility, while having good membrane permeability. In addition, they have a bigger effective two-photon absorption cross section. The compounds of the present invention also have a lower biotoxicity, phototoxicity and photobleaching. There is sufficient difference between the spectral range thereof and that of a biological sample.

Abstract: A heterocyclic compound represented by Formula 1 and an organic light-emitting device including the same. The heterocyclic compound represented by Formula 1 has excellent light emitting characteristics and high charge transporting capabilities.

Abstract: An organic electroluminescence device and a material for producing the organic electroluminescence device. The organic electroluminescence device includes an organic thin film layer between a cathode and an anode, the organic thin film layer including one or more layers, in which the organic thin film layer includes one or more light emitting layers and at least one of the light emitting layers includes a phosphorescent material and a host material. The host material has an essential structure in which a naphthalene ring is bonded to a fluorene skeleton, dibenzofuran skeleton, or dibenzothiophene skeleton. The organic electroluminescence device is a phosphorescent device having high efficiency and long lifetime.

Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, Y1, Y2, or L are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes.

Abstract: In an aspect, an organic compound and an organic light-emitting diode (OLED) including the same are provided.

Abstract: A heterocyclic compound represented by Formula 1 below and an organic light-emitting device including the heterocyclic compound: wherein R1 to R12 are defined as in the specification.

Abstract: Provided are compounds with a donor moiety, a first acceptor moiety and a second acceptor moiety, as shown by Formula (I): With the unique molecular design, compounds of Formula (I) can provide a desirable power conversion efficiency. Moreover, this invention also provides organic thin-film solar cells comprising the above-mentioned compounds.

Abstract: A thiadiazole contains a basic skeleton represented by any of formulae (1), (2), and (3) in the molecule.

Abstract: Provided are a nitrogen-containing aromatic compound useful for an organic electroluminescent device, and an organic electroluminescent device (organic EL device) that improves luminous efficiency of the device and sufficiently ensures driving stability of the device. The nitrogen-containing aromatic heterocyclic compound is represented by the following formula (1). The organic EL device includes an organic layer that contains the nitrogen-containing aromatic heterocyclic compound between an anode and a cathode laminated on a substrate. In the formula (1), a ring A represents an aromatic ring represented by the formula (1a) and fused with two adjacent rings, a ring B represents a heterocycle represented by the formula (1b) and fused with two adjacent rings, Y's each represent C—R or N, X's each represent N—Z, O, S, or Se, R represents hydrogen, an alkyl group, an aromatic group, or the like, and Z represents an alkyl group, an aromatic group, or the like.

Abstract: This invention relates to processes for the preparation of sodium 5,14-dihydrotetraazapentacene polysulfonate (1), and intermediates thereof.

Abstract: A heterocyclic compound includes compounds represented by Formula 1 or Formula 2 below:

Abstract: Herein we describe compositions and methods for the synthesis of [2.2.2]-diazabicyclic structures comprising a domino reaction sequence involving aldol condensation, alkene isomerization, and intramolecular hetero-Diels-Alder cycloaddition. Excellent diastereofacial control during the cycloaddition is enforced with a removable chiral phenyl aminal diketopiperazine substituent. The reaction sequence rapidly generates molecular complexity and is competent with both enolizable and non-enolizable aldehyde substrates. This method provides an efficient route to [2.2.2]-diazabicyclic structures, common to bioactive prenylated indole alkaloids such as the brevianamides and stephacidins.

Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes.

Abstract: The present invention is directed to novel compounds of formula I and their use as anti-angiogenic agents and anti-cancer agents.

Abstract: Disclosed embodiments concern polycyclic alkaloid compounds and methods for their use and synthesis. Particular embodiments concern polycyclic alkaloids having a fused, six-membered ring, while other embodiments concern polycyclic alkaloids having a fused, five-membered ring. Methods for making the polycyclic alkaloids are disclosed, as well as methods for their use as prophylactics or treatments for certain diseases. Also disclosed are pharmaceutical compositions comprising the polycyclic alkaloids and their use.

Abstract: A (+)-3-hydroxymorphinan-based polycycle derivative of formula (I) is effective as a neuroprotective agent for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and ischemic stroke.

Abstract: A species for use, for example, in a charge transfer layer of a photovoltaic device, the species comprising an acceptor group to which is fused a tuning group. The species can be a small molecule, polymer or oligomer, and monomers for producing said polymer, photovoltaic devices comprising said species, and methods for producing said device, are also provided.

Abstract: This invention concerns novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives with binding affinities towards serotonin receptors, in particular 5-HT2A and 5-HT2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.

Abstract: This invention relates to compounds of formula II: wherein R1, R2, ProtSH, and ProtNH are as defined, to processes for the synthesis of ecteinascidins of formula I from compounds of formula II, and to processes for the synthesis of compounds of formula II.

Abstract: The present invention relates to electronic devices, in particular organic electroluminescent devices, comprising compounds of the formula (1), and the corresponding compounds.

Abstract: The present invention provides a nitrogen-containing heterocyclic derivative and an organic electronic device using the same. The nitrogen-containing heterocyclic derivative that is represented by the following Formula 2 or includes two or more structures of the following Formula 2: The organic electronic device according to the present invention has excellent properties in terms of efficiency, driving voltage, and a life span.

Abstract: Provided are compounds with a donor moiety, a first acceptor moiety and a second acceptor moiety, as shown by Formula (I): With the unique molecular design, compounds of Formula (I) can provide a desirable power conversion efficiency. Moreover, this invention also provides organic thin-film solar cells comprising the above-mentioned compounds.

Abstract: A process for preparing 5,7,12,14-tetrahydro-5,7,12,14-tetraazapentacene compounds and derivatives of Formula (A): comprises reacting at least one 1,2-diaminobenzene compound of Formula (I) with a 1,2,4,5-tetrahydroxybenzene compound of Formula (II): wherein R1-R14, Ra-Rj, R?, and R? are as described herein.

Abstract: The present invention relates to compounds of the formula (I) and to the use thereof in organic electronic devices, and to organic electronic devices which comprise compounds of the formula (I), preferably as hole-transport materials and/or as matrix materials, in particular in combination with a further matrix material.

Abstract: The present invention provides compounds of Formula (I-IV): compositions containing the same, and methods of use thereof such as for the treatment of cancer.

Abstract: LED compounds of the general structure: (B-S-)n-A-(- S-B)m (Structure 1); wherein the rod-like molecular nucleus A having the structure: —Ar(-T-Ar)p- (Structure 2); wherein T includes a diradical.

Abstract: A light emitting element includes a light emitting layer that is provided between an anode, a cathode, an anode, and a cathode, and the light emitting layer is configured to include the compound represented by Formula 1 below and the compound represented by Formula RH-1 below. (In Formula 1, A indicates an aryl group, an arylamino group, or triarylamine that may respectively independently include a hydrogen atom, an alkyl group, and a substituent.) (In Formula IRH-1, n indicates a natural number between 1 and 12, and R represents a substituent or a functional group, and indicates an aryl group or an arylamino group that may respectively independently include a hydrogen atom, an alkyl group, and a substituent.

Abstract: A process for preparing 5,7,12,14-tetrahydro-5,7,12,14-tetraazapentacene compounds and derivatives of Formula (A): comprises reacting at least one 1,2-diaminobenzene compound of Formula (I) with a 1,2,4,5-tetrahydroxybenzene compound of Formula (II): wherein R1-R14, Ra-Rj, R?, and R? are as described herein.

Abstract: Compounds of Formula (I) are disclosed: wherein R1-R14, x, y, and z are as defined herein. The compounds are useful as semiconducting materials for electronic devices such as thin-film transistors.

Abstract: A compound of the present invention is represented by the following formula (1): (where: R1 and R2 represent, independently, a substitutable C1 to C20 aliphatic hydrocarbon group; and R3 through R14 represent, independently, one of a hydrogen atom, a halogen atom, a substitutable aliphatic hydrocarbon group, and a substitutable aromatic hydrocarbon group). It is therefore possible to provide a novel compound which can be used as an organic semiconductor material.

Abstract: The present invention relates to quinobenzoxazines analogs having the general formula: and pharmaceutically acceptable salts, esters and prodrugs thereof; wherein A, U, V, W, X and Z are substituents. The present invention also relates to methods for using such compounds.

Abstract: The present invention relates to novel compounds of the formula (I) wherein R1 and R1? independently of each other are H or a substituent, halogen or SiR6R4R5; R2 and R2? may be the same or different and are selected from C1-C25alkyl, C3-C12-cycloalkyl, C2-C25alkenyl, C2-C25alkynyl, C4-C25aryl, C5-C25alkylaryl or C5-C25aralkyl, each of which is unsubstituted or substituted, and under conditions as defined in claim 1, R2 and/or R2? may also be halogen or hydrogen; X is a divalent linking group selected from formula (Ia) and formula (Ib); Y and Y? independently are selected from formula (Ic), formula (Id), formula (Ie), formula (If), formula (Ig); n and p independently range from 0 to 6; where further symbols are as defined in claim 1, and to corresponding oligomers and (co)polymers. The compounds according to the invention are useful as semiconductors and have excellent solubility in organic solvents and excellent film-forming properties.

Abstract: A tetrathiafulvalene derivative expressed by General Formula (I): General Formula (I) in General Formula (I), X represents an atom selected from a carbon atom, a sulfur atom, and a nitrogen atom, and Xs may be the same or different; provided that when X is the carbon atom or the nitrogen atom, R1 to R8 each represent one of a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, and a substituted or unsubstituted thioalkoxy group, and may be the same or different; and Y1 and Y2 each represent one of structures expressed by General Formulas (II) and (III), and may be the same or different: General Formula (II) General Formula (III).

Abstract: An aromatic compound represented by the following formula (1). [In the formula, ring A and ring B each represent a benzene ring, an aromatic fused ring composed of 2-4 rings, a heteroaromatic ring or a heterocyclic aromatic fused ring composed of 2-4 rings, R1a represents a group —CHR2a—CHR2bR2c, and R1b, R1c and R1d each represent hydrogen, aryl or a group —CHR2d—CHR2eR2f. This is with the proviso that at least 2 of R1b, R1c and R1d are not hydrogen. R2a, R2b and R2c each represent hydrogen, alkyl, aryl or a substituted silyl group, and R2a and R2b may be bonded together to form a ring. R2d, R2e and R2f each represent hydrogen, alkyl, aryl or a substituted silyl group, and R2d and R2e may be bonded together to form a ring.

Abstract: The present invention provides a novel nitrogen-containing heterocyclic derivative and an organic electronic device using the same. The organic electronic device according to the present invention has excellent properties in terms of efficiency, driving voltage, and a life span.

Abstract: Derivatives of Et-743 or Et-770 or Et-729 are provided. The derivatives are of the general formula Ia.: wherein the substituent groups take various permitted meanings.

Abstract: The present invention concerns an intermediate of the following formula (I) in which R1 and R2 represent independently of each other a C1-C12 alkyl group, a (C1-C12 alkoxy)carbonyl group, optionally substituted by one, two or three halogen atom, a (C2-C12 alkenyloxy)carbonyl group, an acyl group, a aryl(C1-C12)alkyl group, an arylalkoxy carbonyl group, a (C1-C12 alkyl)sulfonyl group or an arylsulfonyl group, R3 represents a O-protecting group, R4 and R5 represent independently of each other a hydrogen atom or a O-protecting group, R6 represent a O-protecting group and R7 represent a C1-C12 alkyl group or —OR6 and —OR7 form together a group —OCH2O—. The present invention concerns also a process of preparation of the intermediate and its use for the preparation of Ecteinascidin 743 and Ecteinascidin-770.

Abstract: An object of the present invention is to provide a thin optical laminate a refractive index of which is three-dimensionally controlled. The optical laminate of the present invention comprises a retardation layer containing a polycyclic compound having at least one of a —SO3M group and a —COOM group, and having an index ellipsoid satisfying a relationship of nx?nz>ny; and a retardation layer having an index ellipsoid satisfying a relationship of nx?ny>nz. As the polycyclic compound, for example, a quinoxaline derivative represented by the following formula (I) is used.

Abstract: This invention relates to polycyclic organic compounds of a general structural formula (I): wherein Y is a predominantly planar polycyclic system being at least partially aromatic, W1, W2, and W3 are different groups providing solubility in an organic solvent, and sum n1+n2+n3 is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, which are capable of forming supramolecular structures in a wide range of organic solvents, and which are capable of absorbing electromagnetic radiation in at least one subrange of the visible spectral range.

Abstract: The present invention provides a novel nitrogen-containing heterocyclic derivative and an organic electronic device using the same. The organic electronic device according to the present invention has excellent properties in terms of efficiency, driving voltage, and a life span.

Abstract: Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, B1, B2, B3, B4, D1, D2, E1, E2, E3, E4, E5, G1, G2, J, K, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Abstract: This invention relates to polycyclic organic compounds of general structural formula (I): wherein Y is a predominantly planar polycyclic system being at least partially aromatic, W1, W2, and W3 are different groups providing solubility in an organic solvent, and sum (n1+n2+n3) is 1, 2, 3, 4, 5, 6, 7 or 8. The polycyclic organic compounds are substantially transparent for electromagnetic radiation in the visible spectral range and are capable of forming supramolecules in the organic solvent.

Abstract: A process for the preparation of a substituted 2,2?-dithiophene is described, which process comprises the steps (a), (c) and optional steps (b) and (d): a reaction of a compound of the formula: with a suitable lithium organic compound, preferably Li-alkyl or Li-alkylamide; b) optional exchange of lithium against another metal selected from Mg1 Zn and Cu; c) reaction of the metallated intermediate obtained in step (a) or (b) with a suitable electrophil, which is CO2 or an aldehyde (addition reaction), or a compound Y?—R17 or Y?—R18-Z (substitution reaction), where R17 and R18 are as defined in claim 1; and optionally d) modification of the product obtained in step (c), e.g. by introducing one or more conjugating moieties Y ring closure between suitable monovalent residues R17, exchange or extension of functional groups or substituents such as addition to carbonyl or substitution of carbonyl in R17 or R18.

Abstract: This application relates to certain novel polycyclic compounds that interact with quadruplex-forming regions of polynucleotides and thereby inhibit translation of genetic information into polypeptides. These compounds can thus provide anticancer and antibacterial and antiviral effects. The invention includes novel compounds and pharmaceutical compositions, and methods of using them to treat cancer and other conditions.